Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study Investigating the Pharmacokinetic Properties of Cagrilintide in Participants With Various Degrees of Hepatic Impairment and Assessing the Absolute Bioavailability of Subcutaneous Cagrilintide in Healthy Volunteers

NCT05564104 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05564104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05564104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study Investigating the Pharmacokinetic Properties of Cagrilintide in Participants With Various Degrees of Hepatic Impairment and Assessing the Absolute Bioavailability of Subcutaneous Cagrilintide in Healthy Volunteers
Lead sponsor
Novo Nordisk A/S
Phase
Phase 1
Overall status
Completed
Start date
April 5, 2023
Completion date
December 19, 2024
Enrollment
32 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers, hepatic impairment